Literature DB >> 19760123

Chemo-radiotherapy in locally advanced squamous cell oesophageal cancer--are upper third tumours more responsive?

Andras Papp1, Laszlo Cseke, Robert Farkas, Gabor Pavlovics, Gabor Horvath, Gabor Varga, Andras Szigeti, Szabolcs Bellyei, Sandor Marton, Laszlo Poto, Katalin Kalmar, Andras Vereczkei, Eva Pozsgai, Ors Peter Horvath.   

Abstract

Before neoadjuvant therapy was widely applied, the prognosis of oesophageal cancer had been considered dependent on the location of the tumor, i.e. upper third cancers had had the worst prognosis. The aim of this retrolective study was to prove the efficiency of the neoadjuvant treatment, and to compare the response of esophageal cancer in different locations. Between January 1998 and September 2005, 102 patients with locally advanced squamous cell oesophageal cancer received preoperative chemo-radiotherapy. In 40 cases the tumor was located in the upper third and in 62 cases in the middle third of the oesophagus. After a four-week-long treatment free period restaging was carried out and patients considered resectable were submitted to surgery. From 40 patients with upper third oesophageal cancer 28 underwent oesophageal resection or pharyngo-laryngectomy. Thiry-five percent a complete histopathological remission was observed. From 62 patients with middle third oesophageal cancer 43 underwent oesophageal resection. Histological examination of the resected specimens documented complete response only in three patients. The median survival and the R0 resection rate were similar in the two groups. Although the resection rate, perioperative morbidity, mortality and the median survival were similar in the two groups, a significantly higher rate of complete response (p < 0,05) was observed in patients with upper third oesophageal cancer compared to patients with middle third oesophageal cancer. It seems that upper third oesophageal cancer has superior sensitivity to multimodal treatment therefore our results may support that upper third location is not an unfavorable prognostic factor any more.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760123     DOI: 10.1007/s12253-009-9206-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  24 in total

Review 1.  Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies.

Authors:  T Lerut; W Coosemans; G Decker; P De Leyn; P Nafteux; D Van Raemdonck
Journal:  Surg Oncol       Date:  2001-11       Impact factor: 3.279

Review 2.  Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal.

Authors:  Brendan C Visser; Alan P Venook; Marco G Patti
Journal:  Surg Oncol       Date:  2003-07       Impact factor: 3.279

3.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

Review 4.  Gastrointestinal cancers in Europe.

Authors:  M R B Keighley
Journal:  Aliment Pharmacol Ther       Date:  2003-11       Impact factor: 8.171

5.  Esophagus reconstruction with free jejunal transfer.

Authors:  Gabor Pavlovics; Laszlo Cseke; Andras Papp; Gyorgy Tizedes; Bela A Tabar; Peter Ors Horvath
Journal:  Microsurgery       Date:  2006       Impact factor: 2.425

6.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

Authors:  J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

7.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

8.  Larynx-preserving pharyngo-esophagectomy after chemoradiation in the treatment of cancer of the pharyngo-esophageal junction.

Authors:  O P Horváth; L Cseke; K Kalmár; G Varga; G Horváth
Journal:  Ann Thorac Surg       Date:  2001-12       Impact factor: 4.330

9.  The role of multimodality therapy for resectable esophageal cancer.

Authors:  J C Meneu-Diaz; L A Blazquez; E Vicente; J Nuño; Y Quijano; P Lopez-Hervás; M Devesa; V Fresneda
Journal:  Am J Surg       Date:  2000-06       Impact factor: 2.565

10.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

View more
  3 in total

1.  Prognostic role of HPV infection in esophageal squamous cell carcinoma.

Authors:  Laura Bognár; Ivett Hegedűs; Szabolcs Bellyei; Éva Pozsgai; László Zoltán; Katalin Gombos; Örs Péter Horváth; András Vereczkei; András Papp
Journal:  Infect Agent Cancer       Date:  2018-11-29       Impact factor: 2.965

2.  Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer.

Authors:  Yuanmei Chen; Qiuyuan Huang; Junqiang Chen; Yu Lin; Xinyi Huang; Qifeng Wang; Yong Yang; Bijuan Chen; Yuling Ye; Binglin Zheng; Rong Qi; Yushan Chen; Yuanji Xu
Journal:  BMC Cancer       Date:  2021-10-21       Impact factor: 4.430

3.  Site-Specific Variation in Familial Cancer as Suggested by Family History, Multiple Primary Cancer, Age at Onset, and Sex Ratio Associated With Upper, Middle, and Lower Third Esophageal and Gastric Cardia Carcinoma.

Authors:  Denggui Wen; Junpeng Wen; Wendi Zou; Yi Yang; Xiaoduo Wen; Yuetong Chen; Kohei Akazawa; Cuizhi Geng; Baoen Shan
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.